Randomized, Controlled Dose‐Optimization Studies of Dihydroartemisinin‐Piperaquine for the Treatment of Uncomplicated Multidrug‐Resistant Falciparum Malaria in Thailand
The Journal of Infectious Diseases2004Vol. 190(10), pp. 1773–1782
Citations Over TimeTop 10% of 2004 papers
Elizabeth A. Ashley, Srivicha Krudsood, Lucy Phaiphun, Siripan Srivilairit, Rose McGready, Wattana Leowattana, Robert Hutagalung, Polrat Wilairatana, Alan Brockman, Sornchai Looareesuwan, François Nosten, Nicholas J. White
Abstract
The current dosage of DP (6.4 mg/kg DHA and 51.2 mg/kg piperaquine phosphate) given over the course of 48 h is highly effective, safe, and well tolerated for the treatment of multidrug-resistant falciparum malaria, and its efficacy is not improved by the addition of more DHA.
Related Papers
- → Effects of artesunate, dihydroartemisinin, and an artesunate-dihydroartemisinin combination against Toxoplasma gondii.(2000)44 cited
- → Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers(2001)33 cited
- → Preparation of a Novel Monoclonal Antibody against the Antimalarial Drugs, Artemisinin and Artesunate(2007)20 cited
- → Declining Concentrations of Dihydroartemisinin in Plasma during 5-Day Oral Treatment with Artesunate for Falciparum Malaria(1999)64 cited
- → Anticancer Potential of Artemisinin Derivative-Dihydroartemisinin(2023)